Immunization of Patients with Malignant Melanoma with Autologous CD34⁺Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

This publication has 74 references indexed in Scilit:

• Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
  International Journal of Cancer, 2000
• Therapeutic Antitumor Response After Immunization with an Admixture of Recombinant Vaccinia Viruses Expressing a Modified MUC1 Gene and the Murine T-Cell Costimulatory Molecule B7
  Journal of Immunotherapy, 1997
• IL-12 and Mutant P53 Peptide-Pulsed Dendritic Cells for the Specific Immunotherapy of Cancer
  Journal of Immunotherapy, 1996
• Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen
  European Journal of Immunology, 1996
• Cytokine production and antitumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12
  Surgery, 1996
• Tyrosinase and related proteins in mammalian pigmentation
  FEBS Letters, 1996
• G-CSF-Induced Mobilization of Peripheral Blood Stem Cells from Healthy Adults for Allogeneic Transplantation
  Journal of Hematotherapy, 1996
• Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
  The Journal of Experimental Medicine, 1994
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine
  Annals of Surgery, 1992
• Vitiligo in patients with metastatic melanoma: A good prognostic sign
  Journal of the American Academy of Dermatology, 1983